Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Daniel M. Bollag bought 24,700 shares of the firm’s stock in a transaction that occurred on Wednesday, December 6th. The stock was purchased at an average price of $3.93 per share, with a total value of $97,071.00. Following the completion of the purchase, the insider now owns 24,700 shares in the company, valued at $97,071. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Shares of Ocular Therapeutix, Inc. (OCUL) traded up $0.14 during midday trading on Monday, reaching $4.15. 303,500 shares of the company traded hands, compared to its average volume of 862,136. The company has a quick ratio of 4.78, a current ratio of 4.79 and a debt-to-equity ratio of 0.39. Ocular Therapeutix, Inc. has a 12 month low of $3.30 and a 12 month high of $11.79.
Ocular Therapeutix (NASDAQ:OCUL) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.54) EPS for the quarter, hitting the consensus estimate of ($0.54). Ocular Therapeutix had a negative net margin of 3,241.19% and a negative return on equity of 126.31%. The company had revenue of $523.00 million during the quarter, compared to analyst estimates of $0.52 million. During the same quarter in the previous year, the firm earned ($0.39) EPS. The firm’s revenue was up 9.6% compared to the same quarter last year. equities research analysts expect that Ocular Therapeutix, Inc. will post -2.37 earnings per share for the current year.
OCUL has been the subject of several analyst reports. Guggenheim initiated coverage on shares of Ocular Therapeutix in a research note on Monday, October 23rd. They issued a “buy” rating and a $12.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Ocular Therapeutix in a report on Wednesday, November 8th. Zacks Investment Research lowered shares of Ocular Therapeutix from a “hold” rating to a “sell” rating in a report on Wednesday, October 25th. ValuEngine lowered shares of Ocular Therapeutix from a “sell” rating to a “strong sell” rating in a report on Thursday, September 21st. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $21.00 price target on shares of Ocular Therapeutix in a report on Monday, September 25th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. Ocular Therapeutix has an average rating of “Hold” and an average price target of $20.67.
COPYRIGHT VIOLATION NOTICE: “Insider Buying: Ocular Therapeutix, Inc. (OCUL) Insider Buys $97,071.00 in Stock” was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://stocknewstimes.com/2017/12/11/insider-buying-ocular-therapeutix-inc-ocul-insider-buys-97071-00-in-stock.html.
Ocular Therapeutix Company Profile
Ocular Therapeutix, Inc is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery.
Receive News & Ratings for Ocular Therapeutix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.